Daily Roundup

HUB.ASX SOM.ASX SDI.ASX VYS.ASX REH.ASX

HUB24 Delivers Robust Investor Strategy Update

HUB24 Limited held its Investor Strategy Day, showcasing the company's continued market leadership and growth across its platform and technology businesses. The group is uniquely positioned to capitalize on structurally growing markets and industry transformation, driven by increasing demand for advice, shifting demographics, and the separation of aligned advisers to private licensees.

Leveraging its group capabilities, HUB24 is developing innovative solutions to drive efficiencies for financial professionals and their clients. This includes the collaborative integrated advice ecosystem, myhub, which aims to transform adviser productivity. The company is also well-positioned to benefit from the industry's shift towards fewer platform relationships, with a significant growth opportunity from new and existing advisers.

Looking ahead, HUB24 is ideally positioned to leverage emerging technologies, including AI, to create new opportunities and greater efficiency in the wealth management industry. The company's clear strategy for growth, underpinned by its myhub ecosystem and productivity-enhancing solutions, will enable it to capitalize on the structurally growing markets.

SomnoMed Delivers Transformative FY25 Results

SomnoMed Ltd reported a strong set of FY25 results, exceeding its revenue and EBITDA guidance. The company achieved positive operating and free cashflow, demonstrating its ability to execute consistently, scale responsibly, and grow profitably.

SomnoMed made significant operational improvements, including a 50% increase in manufacturing capacity, reduced turnaround times, and the elimination of its backlog. This was enabled by the strengthening of the company's leadership team with several experienced executives.

A key highlight for the year was the FDA clearance of SomnoMed's Rest Assure system, the first oral appliance globally to receive clearance for its compliance monitoring capabilities. This represents an important milestone for the company and the oral appliance therapy category.

Looking ahead, SomnoMed has reaffirmed its FY26 guidance, which includes revenue of $119-$126 million and EBITDA of $10-$12 million. The company remains focused on its ambition to make oral appliance therapy a mainstream treatment for obstructive sleep apnea, leveraging shifting consumer trends and growing interest in alternatives to CPAP.

SDI Ltd Delivers Solid FY25 Performance

SDI Ltd's Chairman addressed shareholders, highlighting the company's solid financial performance in FY25. Despite challenges, including changes to European product registration requirements and underperforming Asian markets, SDI achieved a normalized after-tax profit of $10.5 million, up 0.1% on the previous year.

The company's ongoing focus on aesthetic and whitening products continues to be the strategy for the future direction of its portfolio. SDI also saw good sales growth and positive market feedback for its newest product, Stela, an amalgam and restorative replacement.

Looking ahead, SDI will continue to focus on transitioning its amalgam customers to Stela, the construction of its new 6,500sqm manufacturing plant in Montrose, and ensuring full compliance with the European Union Medical Device Regulation. The company is well-equipped to sell all its products in major markets globally, and the new Montrose facility will increase production capacity and efficiency.

Vysarn Ltd Reports Record FY25 Results

Vysarn Ltd delivered a record FY25 result, with NPBT of $15.0 million, up 36% on FY24. The company is forecasting further strong earnings growth in FY26, targeting NPBT of $20.0 million, representing a 33% increase.

This growth is expected to be driven by continued momentum in the Industrial division, a material second-half skew in the Technology division, and ongoing performance in the Advisory division. Vysarn has also established a national footprint, with new offices opened across Australia and New Zealand.

In its Asset Management division, Vysarn is progressing the Kariyarra Water Scheme, with the completion of the Phase 1 drilling and testing program and upcoming lodgement of the H3 hydrogeological assessment. The company is targeting the launch of an EOI campaign and entry into binding water offtake and infrastructure funding agreements for the project in calendar year 2026.

Reece Announces On-Market Share Buyback

Reece Limited has announced an on-market share buyback of up to $35 million, following the completion of a $365 million off-market buyback in October. The buyback will be funded from Reece's existing cash and debt facilities and is expected to commence on or after 12 December 2025.

Chair & CEO Peter Wilson stated that the company remains committed to maintaining a strong balance sheet with a conservative leverage ratio to fund future growth. The actual number of shares to be purchased and the timing of purchases will depend on market conditions, share price, and other factors.